IL-2 has proven activity against cancer, having been sold as Proleukin (aldesleukin) for kidney and skin cancers since the early 1990s, originally by Chiron and latterly by Clinigen. It is known ...

Aldesleukin is under clinical development by Iltoo Pharma and currently in Phase II for Miscarriage. According to GlobalData, Phase II drugs for Miscarriage does not have sufficient historical data to ...

Five patients with refractory SLE were treated daily with subcutaneous injections of 1.5 million IU of human IL-2 (aldesleukin) for five consecutive days, and PBMC were analysed by flow cytometry.

For homogeneity and proper cross-analyses, we report here the results of the first 46 patients who have been treated with IL-2 as Aldesleukin (Proleukin 18 MIU, Novartis Pharma SAS, Rueil-Malmaison, ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

Inhibition of nonsense-mediated decay turns immunologically cold tumors hot by increasing the amount of mutant RNA leading to an increase in T-cell-targetable neoantigens on the cell surface.

1 Frequency of emesis in the absence of effective antiemetic prophylaxis. 2 May be highly emetogenic in certain patients. 3 Routine premedication may not be required. An individualized approach is ...

Primary non-Hodgkin's lymphoma of the breast (PBNHL) is uncommon. There have been only a few reports of breast lymphoma in the radiology literature. In this case report, we describe mammographic ...

Purpose: The chemical interactions that cause drug incompatibility in solutions, with emphasis on the acid-base and ionized-nonionized forms of organic, weak, electrolyte drugs, are examined ...